



# **EuroThrombosis & EuroVessels 2022**

**20-22 October | Lisbon, Portugal**

**EPIC SANA MARQUÊS Hotel**

## **Programme**

[www.etev2022.com](http://www.etev2022.com)

 **ESC**  
Working Group  
Thrombosis

 **ESC**  
Working Group  
Aorta & Peripheral  
Vascular Diseases

# Organisation, Committees

## Organiser

- **European Society of Cardiology (ESC)**  
Working Group on Thrombosis (WG T)  
Working Group on Aorta and Peripheral Vascular Diseases (WG APVD)  
European Heart House  
Les Templiers  
2035 Route des Colles  
CS 80179 Biot  
06903 Sophia Antipolis Cedex, France  
workinggroups@escardio.org

## Committees

### Executive committee

- **João Morais**, Portugal  
EuroThrombosis & EuroVessels 2022 Chairperson
- **Lucia Mazzolai**, Switzerland  
EuroThrombosis & EuroVessels 2022 Co-Chairperson  
ESC Working Group on Aorta and Peripheral Vascular Diseases Past-Chairperson
- **Gemma Vilahur**, Spain  
EuroThrombosis & EuroVessels 2022 Co-Chairperson  
ESC Working Group on Thrombosis Past-Chairperson
- **Victor Aboyans**, France  
EuroThrombosis & EuroVessels 2022 Co-Chairperson  
ESC Working Group on Aorta and Peripheral Vascular Diseases Past-Chairperson
- **Dirk Sibbing**, Germany  
EuroThrombosis & EuroVessels 2022 Co-Chairperson  
ESC Working Group on Thrombosis Past-Chairperson

### Scientific committee

- **Andrea Rubboli**, Italy  
ESC Working Group on Thrombosis Chairperson
- **Oliver Schlager**, Austria  
ESC Working Group on Aorta and Peripheral Vascular Diseases Chairperson
- **Diana Gorog**, United Kingdom  
ESC Working Group on Thrombosis Chairperson-Elect
- **Marco De Carlo**, Italy  
ESC Working Group on Aorta and Peripheral Vascular Diseases Past-Chairperson
- **Bianca Rocca**, Italy  
ESC Working Group on Thrombosis Past-Chairperson

## Meeting secretariat

- **FactorChave**  
Miraflores Office Center, Avenida das Tulipas, n.º 6, 19.º  
1495-161 Algés, Portugal  
www.factorchave.pt  
etev2022@etev2022.com

# Welcome

Dear Colleagues,

EuroThrombosis, EuroVessels 2022 is a joint scientific meeting organized by the Working Group on Thrombosis and the Working Group on Aorta and Peripheral Vascular Diseases of the European Society of Cardiology (ESC).

In 2022 we are recovering from a long dark period related to the devastating pandemic affecting the global world. For this recovery nothing better than a face-to-face scientific meeting.

For this purpose, an intense three-day scientific programme will update you from basic science to translational medicine and clinical practice in the areas of atherosclerosis, vascular biology and atherothrombosis.

Topics will include coronary artery disease, peripheral arterial disease, atrial fibrillation, stroke, aortic syndromes and cardiovascular prevention. Pharmacotherapy and the use of endovascular devices will form a substantial part of the meeting, giving to the clinician an update in order to guide and encourage optimal day-to-day clinical practice.

At this meeting, the etiology and basic principles of these conditions and disease states will be explored in depth, to drive forward research and innovation in these areas. Basic and translational science will be presented alongside the latest concepts in diagnosis and treatment.

A significant part of the meeting will be dedicated to the presentation of original clinical and translational research in poster format, allowing the exchange of ideas and experience among researchers and clinicians.

The scientific programme will be delivered by an expert faculty consisting of the most prominent European names in the respective areas.

Alongside opportunities for education and learning, the possibilities for networking between young clinicians/scientists and experienced researchers, clinicians and faculty elements will create unique opportunities for development of new ideas and future collaboration.

The beautiful city of Lisbon, repeatedly named as one of the best tourist destinations in Europe, is the perfect setting for this outstanding scientific event. Being modern but also associated with great traditions, Lisbon has a special atmosphere and ambience recognized by all visitors.

EuroThrombosis, EuroVessels 2022 will become an important milestone in continuing medical education in 2022. We very much hope you will be able to share in this exciting, cutting-edge meeting with us.

Gemma Vilahur  
WG Thrombosis

João Morais  
ETEV 2022 Chairperson

Lucia Mazzolai  
WG Aorta and Peripheral  
Vascular Diseases

# Meeting at a glance

		08:00	09:00	10:00	11:00	12:00	13:00	14:00
<b>Thursday 20 October</b>	Room A	Registration						
	Room B	Registration						
	Room C	Registration						
	EXHIBITION & POSTER HALL							
<b>Friday 21 October</b>	Room A	Registration						
	Room B	Speaker Service Centre						
	Room C	Speaker Service Centre						
	EXHIBITION & POSTER HALL	Case-based session	Unrevealing the complexity of thrombosis in ACS	POSTERS	Diabetes: targeting the increase in cardiovascular risk	Oral Presentations		
	Room A	Oral Presentations	New concepts on old vascular disease	POSTERS	Lower Extremity Artery Disease: improved management for better outcome	Oral Presentations		
	Room B	Oral Presentations						
	Room C	Oral Presentations						
		EXHIBITION						
<b>Saturday 22 October</b>	Room A	Registration						
	Room B	Speaker Service Centre						
	Room C	Speaker Service Centre						
	EXHIBITION & POSTER HALL	Moderated posters	Update on antithrombotic strategies	POSTERS	Optimizing outcomes in Vascular Surgery Joint Session with the European Society of Vascular Surgery	Closing session		
	Room A	Oral Presentations	Aorta - What's new since the 2014 guidelines?	POSTERS	Predictive Biomarkers			
	Room B	Oral Presentations						
	Room C	Oral Presentations						
		EXHIBITION						

00	14:30	15:00	15:30	16:00	16:30	17:00	17:30	18:00	18:30	19:00	19:30	20:00	20:30
Speaker Service Centre													
Opening lecture	New avenues for combating atherothrombosis		POSTERS	Challenges in antithrombotic therapy in special populations		Fontaine Lecture	Industry Satellite Symposium						
	New avenues for combating venous thromboembolism			Coronary Microcirculatory Dysfunction Joint Session with the ESC WG on Coronary Pathophysiology, Microcirculation									
EXHIBITION											Welcome Reception		

Speaker Service Centre												
Antithrombotics in non-coronary interventions		POSTERS	Novel approaches in LEAD Joint Session with the European Society of Vascular Medicine		Steen Husted Lecture	ESC WG on Thrombosis General Assembly						
Platelets in atherosclerosis and vascular biology: beyond thrombosis Joint Session with the ESC WG on Atherosclerosis and Vascular Biology			Prevention strategies in the continuum of CV risk									

00	14:30	15:00	15:30	16:00	16:30	17:00	17:30	18:00	18:30	19:00	19:30	20:00	20:30

# Faculty

**Agneta Siegbahn** | Uppsala University, Uppsala (Sweden)  
**Alexandre Persu** | Cliniques Saint-Luc UCL, Brussels (Belgium)  
**Andrea Rubboli** | Santa Maria delle Croci Hospital, Ravenna (Italy)  
**Arina ten Cate-Hoek** | Fac. Health, Medicine and Life Sciences, Biochemie, Maastricht (The Netherlands)  
**Bianca Rocca** | Catholic University School of Medicine, Rome (Italy)  
**Bruna Gigante** | Karolinska Institutet, Stockholm (Sweden)  
**Carlo Patrono** | Catholic University of the Sacred Heart, Rome (Italy)  
**Carlos Aguiar** | Centro Hospitalar de Lisboa Ocidental - Hospital Santa Cruz, Lisbon (Portugal)  
**Cecilia Becattini** | University of Perugia, Perugia (Italy)  
**Christian Heiss** | University of Surrey, Guildford (United Kingdom)  
**Christian Torp-Pedersen** | Nordsjaellands Hospital, Hilleroed (Denmark)  
**Christina Christersson** | Uppsala University, Uppsala (Sweden)  
**Christine Espinola-Klein** | University Medical Center of Mainz, Mainz (Germany)  
**Christopher Twine** | Bristol Medical School, Bristol (United Kingdom)  
**Cristina Gavina** | Unidade Local de Saúde de Matosinhos - Hospital Pedro Hispano, Porto (Portugal)  
**Daniel Caldeira** | Centro Hospital de Lisboa Norte - Hospital de Santa Maria, Lisboa (Portugal)  
**Diana Gorog** | University of Hertfordshire, London (United Kingdom)  
**Diederick Grobbee** | University Medical Center Utrecht, Utrecht (The Netherlands)  
**Dirk Duncker** | Erasmus MC, University Medical Centre Rotterdam, Rotterdam (The Netherlands)  
**Eduardo Infante de Oliveira** | Hospital Lusíadas Lisboa, Lisbon (Portugal)  
**Francisco Araújo** | Hospital Lusíadas Lisboa, Lisbon (Portugal)  
**Frank Vermassen** | Ghent University Library, Ghent (Belgium)  
**Gemma Vilahur** | Hospital de la Santa Creu i Sant Pau, Barcelona (Spain)  
**Gerry Fowkes** | Edinburgh (United Kingdom)  
**Giacomo Buso** | University Hospital Centre Vaudois (CHUV), Lausanne (Switzerland)  
**Heleen Van Beusekom** | Erasmus MC University Medical Centre, Rotterdam (The Netherlands)  
**Hugo ten Cate** | Cardiovascular Research Institute Maastricht (CARIM), Maastricht (The Netherlands)  
**Ingebjorg Seljeflot** | Oslo University Hospital Ullevaal, Oslo (Norway)  
**Jill Belch** | University of Dundee (United Kingdom)  
**João Morais** | Centro Hospitalar de Leiria, Leiria (Portugal)  
**Johann Wotja** | Medical University of Vienna, Vienna (Austria)  
**Jolanta Siller Matula** | Medical University of Vienna, Vienna (Austria)  
**José Rodríguez Palomares** | University Hospital Vall d'Hebron, Barcelona (Spain)  
**Julie Debacker** | University Hospital Ghent, Gent (Belgium)

---

**Juraj Madaric** | National Institute of Cardiovascular Diseases, Bratislava (Slovakia)

**Jurrien Ten Berg** | St Antonius Hospital, Nieuwegein (The Netherlands)

**Lars Wallentin** | Uppsala University, Uppsala (Sweden)

**Lina Badimon** | Research Institute-Hospital de la Santa Creu i Sant Pau, IIBSant Pau, CiberCV, Barcelona, Spain

**Lucia Mazzolai** | University Hospital Centre Vaudois (CHUV), Lausanne (Switzerland)

**Luís Mendes Pedro** | Hospital da Luz, Lisboa (Portugal)

**Manuel Mayr** | King's British Heart Foundation Centre, London (United Kingdom)

**Marco De Carlo** | Azienda Ospedaliero Universitaria Pisana, Pisa (Italy)

**Marianne Brodmann** | Medical University of Graz, Graz (Austria)

**Marie-Luce Bochaton-Piallat** | University of Geneva, Geneva (Switzerland)

**Martin Czerny** | University Heart Center, Freiburg (Germany)

**Nuno Dias Ferreira** | Centro Hospitalar de Vila Nova de Gaia/Espinho, Porto (Portugal)

**Oliver Schlager** | Medical University of Vienna, Vienna (Austria)

**Pedro Matos** | Hospital CUF Tejo, Lisboa (Portugal)

**Ramzi Ajjan** | Leeds (United Kingdom)

**Robert Storey** | University of Sheffield, Sheffield (United Kingdom)

**Roland van Kimmenade** | University Medical Centre St Radboud (UMCN), Nijmegen (The Netherlands)

**Rory Koenen** | Cardiovascular Research Institute Maastricht (CARIM), Maastricht (The Netherlands)

**Rui Baptista** | Centro Hospitalar de Entre o Douro e Vouga, Aveiro (Portugal)

**Rupert Bauersachs** | CCB at Agaplesion Bethanien Hospital, Frankfurt am Main (Germany)

**Sigrun Halvorsen** | Oslo University Hospital Ullevål, Oslo (Norway)

**Teresa Padró** | Cardiovascular Program-ICCC, IR-Hospital Santa Creu i Sant Pau, CIBERCV, Barcelona (Spain)

**Tobias Geisler** | University Hospital of Tuebingen, Tuebingen (Germany)

**Tristan Mirault** | University Paris City PARCC INSERM U970 European Hospital Georges Pompidou APHP, Paris (France)

**Victor Aboyans** | University Hospital of Limoges, Limoges (France)

# Thursday, 20 October

14:00 - 14:25

**ROOM A | Opening lecture**

Chair: João Morais

- **ATHEROTHROMBOSIS: a contemporary overview and a glimpse into the future** | Lars Wallentin

14:30 - 16:00

**ROOM A | New avenues for combating atherothrombosis**

Chairs: Carlos Aguiar, Robert Storey

- **The era of personalized medicine on antithrombotics** | Carlo Patrono
- **LDL-cholesterol and beyond** | Carlos Aguiar
- **New developments in P2Y12 blockade** | Robert Storey
- **Repurposing old drugs targeting inflammation** | Bruna Gigante

**ROOM B | New avenues for combating venous thromboembolism**

Chairs: Lucia Mazzolai, Bianca Rocca

- **Pulmonary embolism: for whom revascularization is an option?** | Marianne Brodmann
- **Deep vein thrombosis: for whom revascularization is an option?** | Oliver Schlager
- **Personalized treatment of VTE in non cancer patients** | Rupert Bauersachs
- **Personalized treatment of VTE in cancer patients** | Cecilia Becattini

16:00 - 16:30 | Posters & coffee break

16:30 - 17:55

**ROOM A | Challenges in antithrombotic therapy in special populations**

Chairs: Daniel Caldeira, Christine Espinola-Klein

- **Cardiogenic shock** | Diana Gorog
- **Polyvascular atherosclerotic disease** | Victor Aboyans
- **The elderly and the very elderly** | Andrea Rubboli
- **Chronic kidney disease** | Christian Torp-Pedersen

**ROOM B | Coronary Microcirculatory Dysfunction**

Joint Session with the ESC WG on Coronary Pathophysiology, Microcirculation

Chairs: Teresa Padró, Jolanta Siller Matula

- **Role of coronary microvascular dysfunction in cardiovascular disease** | Dirk Duncker
- **Ischemic heart disease in women: Risk Factors and Pathophysiology** | Teresa Padró
- **How to address the no-reflow phenomenon in ACS** | Jolanta Siller Matula
- **INOCA, a permanent challenge to our knowledge** | Nuno Dias Ferreira

18:00 - 18:25

**ROOM A | Fontaine Lecture**

Chairs: Victor Aboyans, Gemma Vilahur

- **Global Burden PAD** | Gerry Fowkes



---

18:30 - 19:15

ROOM A | Industry Satellite Symposium - Amarin

**One step further in reducing established cardiovascular disease risk:  
targeting atherothrombosis after REDUCE-IT**

Chair: João Morais

- Established CVD and atherothrombosis: how did we get here and how can we get out | Francisco Araújo
- Icosapent Ethyl, a new player in reducing atherothrombotic risk? | Victor Aboyans

19:15 - 20:15

Welcome Reception

# Friday, 21 October

08:00 - 08:55

## ROOM A | Case-based session

Organised by the ESC WG on Thrombosis Young Researchers

Chairs: Andrea Rubboli, Christina Christersson

Discussants: Eduardo Infante de Oliveira, Diana Gorog

CC3 | Coronary Subclavian Steal Syndrome: an unusual cause of Acute Myocardial Infarction | Ana Isabel Pinho

CC4 | Percutaneous Patent Foramen Ovale Closure after a Thrombotic Storm: A Case Report | David Sá-Couto

CC17 | A catastrophic case of ischemic stroke and acute myocarditis in a young patient following mRNA COVID-19 vaccination: coincidence or consequence? | Jéni Quintal

CC31 | Active gastrointestinal bleeding during STEMI: a management dilemma | Vanessa Lopes

## ROOM B | Oral Presentations | Thrombosis and antithrombotic strategies I

Chairs: Ingebjorg Seljeflot, João Morais

OP82 | Pre-treatment with Dual Antiplatelet Therapy in NSTEMI-ACS: not always, not ever | António Rocha de Almeida

OP83 | Coronary Aspiration Thrombectomy: bringing back the old kid on the block | António Rocha de Almeida

OP107 | Achieving higher efficacy without compromising safety with Factor XI inhibitors versus low-molecular-weight heparin for the prevention of venous thromboembolism in major orthopedic surgery | João Presume

OP112 | Treatment of pulmonary embolism after paradoxical stroke | Mariana Martinho

OP114 | Small-bore aspiration thrombectomy versus catheter-directed thrombolysis in intermediate-high risk acute Pulmonary Embolism | Mariana Martinho

## ROOM C | Oral Presentations | Hematological biomarkers and prognostic implications

Chairs: Rory Koenen, Heleen Van Beusekom

OP32 | The interplay between VWF, ADAMTS13 and TSP1, and their relation to clinical endpoints | Ellen Mathea Kirsch Warlo

OP41 | High plasma von Willebrand factor concentration is associated with the development of bleeding complications in patients with polyvascular disease receiving multicomponent antithrombotic therapy | Elena Krivosheeva

OP55 | Is White Blood Count a Good Marker to Coronary Disease Risk? | Débora Sá

OP56 | Elevated White Blood Cells Count and C-Reactive Protein as markers for coronary heart disease prognosis | Débora Sá

OP68 | Plasma fibrinogen independently predicts hypofibrinolysis in severe COVID-19 | Diana Schrick

09:00 - 10:30

## ROOM A | Unrevealing the complexity of thrombosis in ACS

Chairs: Lina Badimon, Bruna Gigante

- Cardiac benefits of P2Y12 inhibitors beyond their antiplatelet properties | Gemma Vilahur
- Monocyte and macrophage subsets in coronary artery disease and beyond | Johann Wotja
- Epigenetics in atherothrombosis | Manuel Mayr
- Factor Xa and platelet activation | Daniel Caldeira



### **ROOM B | New concepts on old vascular disease**

Chairs: Oliver Schlager, José Rodríguez Palomares

- Clinical Case | Giacomo Buso
- Fibromuscular Disease: no more reason to ignore it | Alexandre Persu
- Clinical Case | Giacomo Buso
- Aortic tortuosity: assessment and clinical consequences | Roland Van Kimmenade

10:30 - 11:00 | Posters & coffee break

11:00 - 12:25

### **ROOM A | Diabetes: targeting the increase in cardiovascular risk**

Chairs: Carlo Patrono, Pedro Matos

- Myocardial Revascularization: A permanent challenge in Diabetes | Eduardo Infante de Oliveira
- Managing glucose metabolism: does glycemia still matter? | Ramzi Ajjan
- How to stratify risk in diabetic patients | Pedro Matos
- Platelet inhibition | Bianca Rocca

### **ROOM B | Lower Extremity Artery Disease: improved management for better outcome**

Chairs: Marco De Carlo, Frank Vermassen

- Optimal pharmacotherapy | Tristan Mirault
- Best Exercise training modalities | Lucia Mazzolai
- Endovascular revascularization? What we know and where we are heading to | Frank Vermassen
- Biomarkers in LEAD | Christian Heiss

12:30 - 13:45

### **ROOM A | Oral Presentations | Insights on vascular biology and disease**

Chairs: Roland van Kimmenade, Tristan Mirault

OP6 | Postoperative Myocardial Injury due to Platelet Reactivity in Patients undergoing Vascular Surgery | Kai Zheng

OP48 | Sex-based differences in patients with peripheral arterial disease admitted for acute coronary syndrome - Insights from a multicentre national registry | Margarida Cabral

OP75 | Impact of thoracic aortic calcification measured by computed tomography in clinical outcomes in patients undergoing cardiac surgery | Margarida Cabral

OP89 | Vascular access computed tomography angiography-derived iliofemoral calcium volume in the evaluation of vascular and bleeding complications after transfemoral TAVI | Mariana Ribeiro Silva

OP91 | Valve-in-valve TAVI for treatment of degenerated surgical aortic bioprosthesis | Mariana Ribeiro Silva

OP121 | Aortic stiffness descriptors by cardiac magnetic resonance are correlated with mechanical testing of ex-vivo aortic aneurysms specimens | Aroa Ruiz Muñoz

OP125 | Relation of non-invasively measured ankle-brachial index and pulse-wave velocity towards all-cause mortality in unselected emergency department patients - a prospective cross-sectional study | Oliver Schlager



## **ROOM B | Oral Presentations | Basic knowledge to understand thrombosis**

Chairs: Gemma Vilahur, Johann Wotja

- OP3 | Growth differentiation factor-15 and bleeding complication risk in patients with coronary artery disease, receiving combined antithrombotic therapy | Elena Krivosheeva
- OP19 | Bi-directional cross talk between coagulation, fibrinolysis and inflammatory pathways in patients with ST-segment elevation myocardial infarction | Rahim Kanji
- OP46 | The effect of covid-19 vaccine on the endothelial function | Ahmed Makni
- OP90 | Pleiotropic effect of antiplatelet ticagrelor: expression of CYP4F2 in HUVEC and HepG2 | Ieva Ciapiene
- OP93 | Assessing different noncoding RNAs as markers of platelet reactivity | Clemens Gutmann
- OP105 | Endothelial dysfunction and alterations in erythrocyte function in a murine model of chronic heart failure | Tasnim Mohaissen
- OP64 | Elevated soluble glycoprotein VI, a specific predictor of bleeding risk in patients with chronic coronary syndromes undergoing percutaneous coronary intervention | Shqipdona Lahu

14:10 - 15:40

## **ROOM A | Antithrombotics in non-coronary interventions**

Chairs: Christopher Twine, Tobias Geisler

- TAVI | Jurrien Ten Berg
- Left Atrial Appendage and PFO | Tobias Geisler
- Peripheral revascularization | Marco De Carlo
- Aortic endovascular therapy | Christopher Twine

## **ROOM B | Platelets in atherosclerosis and vascular biology: beyond thrombosis**

Joint Session with the ESC WG on Atherosclerosis and Vascular Biology

Chairs: Marie-Luce Bochaton-Piallat, Gemma Vilahur

- Platelet-derived extracellular vesicles, chemokines and cell adhesion molecules in atherosclerosis | Rory Koenen
- Platelet-derived EVs as biological players after myocardial infarction - good or bad? | Christina Christersson
- The (not so) smooth muscle cell in atherosclerosis | Marie-Luce Bochaton-Piallat
- Vascular injury and repair and the journey of microthrombi following mechanical thrombectomy | Heleen Van Beusekom

15:40 - 16:00 | Posters & coffee break

16:00 - 17:25

## **ROOM A | Novel approaches in Lower Extremity Artery Disease (LEAD)**

Joint Session with the European Society of Vascular Medicine

Chairs: Oliver Schlager, Victor Aboyans

- Supervised exercise training in LEAD: alternative or adjuvant to revascularization? | Christine Espinola-Klein
- Interventional management of calcified arterial lesions | Marianne Brodmann
- Regenerative therapy in no-option chronic limb threatening ischemia | Juraj Madaric
- Air pollution and Critical Limb Ischemia | Jill Belch

---

**ROOM B | Prevention strategies in the continuum of CV risk**

**Chairs:** Francisco Araújo, Tobias Geisler

- Effects of exercise training on atherothrombotic risk | Ingebjorg Seljeflot
- The polypill in primary and secondary prevention. Where do we stand? | Diederick Grobbee
- Preventive strategies in patients with CKD | Rui Baptista
- Association between influenza vaccination and cardiovascular diseases | Tobias Geisler

17:30 - 17:55

**ROOM A | Steen Husted Lecture**

**Chairs:** Bianca Rocca, Lucia Mazzolai

- Current advances in ischemic stroke research and therapies | Heleen Van Beusekom

18:00 - 18:30

**ROOM A | ESC WG on Thrombosis General Assembly**

- General information to members of the Working Group (ongoing and upcoming activities)

# Saturday, 22 October

08:00 - 08:55

## ROOM A | Moderated posters

Chairs: Heleen Van Beusekom, Marco De Carlo

PO12 | Premature myocardial infarction: a decade-long analysis of patients admitted to a single-center coronary care unit | Vanessa Lopes

PO106 | Can we optimize d-dimer cut off value to predict pulmonary embolism in covid-19 patients? | Rafaela Fernandes

PO52 | The Influence of the CYP2C9 polymorphisms on the treatment with clopidogrel: combined data from the POPular Genetics & POPular AGE trials | Wout van den Broek

PO109 | Prognostic value of white blood cell count variation during in-hospital stay in STEMI patients: Insights from SCALIM Registry. | Pierre Chenard

PO122 | Predicting the rate of progressive dilation by wall shear stress in bicuspid aortic valve patients | José Rodríguez-Palomares

## ROOM B | Oral Presentations | Thrombosis and antithrombotic strategies II

Chair: Diana Gorog

OP34 | A Case Series of patients with Pulmonary Embolism during post COVID-19 period | Elena Leonidou

OP53 | Dose-related preprocedural patency of the infarct-related artery after zilverflex (RUC-4) administration upon arrival at the catheterization laboratory in ST-elevation myocardial infarction: insights from the phase IIa study | Sem A.O.F. Rikken

OP67 | Thrombotic Events in COVID-19 Patients Admitted at Chinese General Hospital and Medical Center | Joel Santos

OP79 | Quality of life in patients after pulmonary embolism. Correlation with echocardiographic and biochemical parameters. | Olga Kardakari

OP126 | NOACs safety and efficacy in Adult Congenital Heart Disease | Cátia Oliveira

## ROOM C | Oral Presentations | Brief tips useful for the clinicians

Chairs: Andrea Rubboli, Bruna Gigante

OP69 | Chronotropic incompetence: still a suitable indicator? | Isabel Cruz

OP81 | A STEMI case with sub-occlusive lesion and high thrombotic burden - discussing a tailored approach | Maria Rita Lima

OP84 | Initial clinical experience with 6-hour enoxaparin regimen in opiate-treated patients undergoing primary percutaneous coronary intervention | Nadir Elamin

OP96 | Impact of inflammatory and hematological factors to the left ventricle function, remodeling, and clinical outcomes after the first myocardial infarction | Nina Korac

OP10 | Pharmacological therapy in patients with myocardial infarction with nonobstructive coronary arteries (MINOCA): long-term prognosis | Vanessa Lopes

09:00 - 10:30

## ROOM A | Update on antithrombotic strategies

Chairs: Sigrun Halvorsen, João Morais

- Antithrombotic strategies after AMI | Cristina Gavina
- Dual pathway in atherothrombotic disorders | João Morais
- Management of anti-thrombotic treatment in patients undergoing non-cardiac surgery | Sigrun Halvorsen
- Ongoing preclinical and clinical trials on FXIa and FXIIa | Hugo ten Cate

---

**ROOM B | Aorta - What's new since the 2014 guidelines?**

Chairs: Luís Mendes Pedro, Martin Czerny

- Genetics of Aortic Diseases | Julie Debacker
- New multimodality imaging techniques of the thoracic and abdominal aorta | José Rodríguez Palomares
- Type B aortic dissection: when to intervene | Martin Czerny
- Ruptured AAA: from prevention to intervention | Frank Vermassen

10:30 - 11:00 | Posters & coffee break

11:00 - 12:25

**ROOM A | Optimizing outcomes in Vascular Surgery**

Joint Session with the European Society of Vascular Surgery

Chairs: Lucia Mazzolai, João Morais

- Should we continue to screen cardiac diseases prior to peripheral revascularization? | Marco De Carlo
- Optimal medical treatment of candidates to Vascular Surgery in 2022 | Christopher Twine
- Peri-operative management of antithrombotic therapies | Christine Espinola-Klein
- Follow-up after vascular intervention | Christian Heiss

**ROOM B | Predictive Biomarkers**

Chairs: Bruna Gigante, Cristina Gavina

- Biomarkers of bleeding | Agneta Siegbahn
- Biomarkers of arterial thrombosis | Lina Badimon
- Biomarkers of fibrinolysis | Diana Gorog
- Biomarkers of venous thrombosis | Arina ten Cate-Hoek


12:30 - 13:00

**ROOM A | Closing session**

- Poster awards and closure of conference | João Morais, Andrea Rubboli, Oliver Schlager



Bronze Sponsors



Daiichi-Sankyo

With the support of



Others



This International Conference is supported by Bayer, Daiichi-Sankyo, Tourism of Lisbon, Amarin, AstraZeneca, Evigation and Mobit in the form of an educational grant.

The scientific programme has not been influenced in any way by its sponsors.



**Meeting Secretariat**  
FactorChave

Miraflores Office Center, Avenida das Tulipas, n.º 6, 19.º  
1495-161 Algés, Portugal

[etev2022@etev2022.com](mailto:etev2022@etev2022.com) | [www.etev2022.com](http://www.etev2022.com)